Metabolic Syndrome

Homocysteine (Hcy)
S-Adenosyl-L-Homocysteine (SAH)
Trimethylamine N-Oxide (TMAO)
Catechol-O-Methyltransferase (COMT)
Small intestine Bacterial Overgrowth (SIBO)

Genetic polymorphisms in the CCR5 gene, notably the CCR5-Δ32 mutation, provide significant survival advantages and near-complete resistance to R5-tropic HIV-1 infection.

..

hiv-2 type-2 malaria similarities mitochondria glycolysis oxidative phosphorylation homocysteine

HIV-2 and Malaria (specifically Plasmodium falciparum) share critical pathogenic mechanisms involving mitochondrial dysfunction, altered cellular energetics (glycolysis/oxidative phosphorylation), and increased homocysteine levels, particularly in the context of co-infection. Both pathogens, although genetically distinct, create a high-oxidative-stress environment that damages host cell metabolism, leading to accelerated disease progression.

Key Similarities:
HIV-2 and Malaria

Mitochondrial Dysfunction:HIV-2: HIV-2 infection (similar to HIV-1) and antiretroviral therapy (ART) cause profound mitochondrial damage, including decreased membrane potential and mtDNA damage. HIV-2 specifically causes metabolic remodeling in macrophages, often reducing the efficiency of oxidative phosphorylation (OXPHOS) and promoting mitochondrial dysfunction.

Malaria: Malaria causes the single mitochondrion of the parasite to undergo morphological changes and reduces its reliance on OXPHOS, instead relying on host-derived glycolysis. It also triggers mitochondrial reactive oxygen species (mROS) production in host cells (monocytes).

Glycolysis and Oxidative Phosphorylation (OXPHOS):

Both pathogens shift the host cell's metabolic profile towards aerobic glycolysis (the Warburg effect), decreasing reliance on OXPHOS to meet energy demands and support replication or parasite development.

HIV-2: HIV-2 infected macrophages display metabolic changes that enhance glycolysis and the pentose phosphate pathway, similar to HIV-1, but with increased quinolinate production.

Malaria: P. vivax (and P. falciparum) infected cells increase glucose uptake and elevate ATP production through glycolysis rather than OXPHOS.

Homocysteine and Oxidative Stress:

Both diseases are associated with hyperhomocysteinemia (high levels of homocysteine in the blood).

HIV-2/HIV-1: HIV infection and ART, particularly NRTIs, are associated with higher plasma homocysteine and decreased folate levels, indicative of increased oxidative stress.

Malaria: Acute P. falciparum malaria causes elevated homocysteine, which positively correlates with disease severity and negatively correlates with hemoglobin levels, likely due to an imbalance in the folate cycle, oxidative stress, and nutrient depletion.

Co-infection Dynamics:

HIV-2-infected individuals (particularly those with lower CD4+ counts) are more susceptible to severe malaria.

Malaria infection, in turn, acts as a temporary catalyst for HIV progression, increasing the viral load (HIV-1 and by implication, increasing immune activation for HIV-2) during acute episodes, largely driven by enhanced inflammatory cytokine production.

Hematological Abnormalities: Both conditions, particularly when concurrent, lead to significant hematological, such as severe anemia, thrombocytopenia, and leucopenia.

Differences in Mechanisms

Virus vs. Parasite: HIV-2 is a retrovirus that integrates into the host genome, whereas Malaria is a parasite that lives primarily within red blood cells, using the host cell for trafficking and metabolism.

Energy Generation: While both increase glycolysis, malaria parasites specifically use their own glycolysis pathways to consume host glucose, while HIV-2 induces a global cellular shift to glycolysis.

..

SAM/SAH ratio SAHH BHMT AHCY Hydrolase methyltransferase homocysteine high SAH buildup acetylcholine phospholipid enzyme Vitamin B zinc ch3 methyl donor triglycerides

The SAM/SAH ratio (S-adenosylmethionine to S-adenosylhomocysteine), often called the "methylation index," is a critical indicator of cellular methylation capacity. SAM acts as the primary methyl donor (-CH3) in methylation reactions (DNA, proteins, phospholipids), and is converted into SAH.

SAH is a potent inhibitor of methyltransferase enzymes, which catalyze methyl transfer reactions. AHCY/SAHH (S-adenosylhomocysteine hydrolase) is the sole enzyme that breaks down SAH into homocysteine and adenosine. High SAH buildup (low SAM/SAH ratio) typically indicates a failure of this enzyme to remove SAH, leading to inhibition of methylation processes.

Key Connections:
SAM/SAH Ratio and Methylation Capacity: A high ratio signifies robust methylation capacity. A low ratio (<9–50) is associated with nutrient deficiency (B12, Folate), oxidative stress, or enzyme malfunctions, leading to reduced methylation potential.

High SAH Buildup: Elevated SAH inhibits methyltransferases (COMT) by binding to their active sites. This results in a "methylation brake," causing reduced synthesis of neurotransmitters (like acetylcholine), impaired DNA repair, and reduced synthesis of phospholipids.

AHCY/SAHH Enzyme Function: AHCY converts SAH to homocysteine. It requires a redox cofactor, NAD+. Its activity is essential to prevent feedback inhibition from accumulating SAH.

BHMT (Betaine-Homocysteine Methyltransferase): An enzyme that remethylates homocysteine to methionine using choline as a methyl donor. It operates as a safety valve in the cycle, providing an alternative to the folate pathway for regenerating SAM, particularly in the liver.

Phospholipids and Triglycerides: High SAH inhibits the methylation of phosphatidylethanolamine to phosphatidylcholine (a crucial phospholipid for cell membranes) via the PEMT pathway. Impaired methylation can lead to abnormal lipid metabolism and is linked to fatty liver (steatosis), where phosphatidylcholine deficiency affects triglyceride transport.

Vitamin B and Zinc: Essential cofactors for the cycle. B12 is needed for homocysteine recycling to methionine (MS enzyme). Folate (B9) and Riboflavin (B2) are required for MTHFR enzyme activity. B6 is required for the transsulfuration pathway (converting Hcy to glutathione). Zinc aids in stabilizing enzymes involved in this pathway.

Pathological Impact: Low SAM/SAH ratios (high SAH) are associated with neurodegenerative disorders, cardiovascular risk, liver diseases, and cancer due to reduced DNA/protein methylation.

..

Spondyloarthropathies (SpA), including ankylosing spondylitis (AS) and psoriatic arthritis (PsA), are chronic inflammatory conditions characterized by immune-mediated joint and enthesitis (inflammation where tendons/ligaments meet bone) damage. Research suggests a connection between these diseases and metabolic/nutrient imbalances, specifically high triglycerides, elevated homocysteine, potential S-adenosylhomocysteine (SAH) buildup, and imbalances in acetylcholine and phospholipid metabolism.

..

Chronic HIV infection and long-term Antiretroviral Therapy are strongly associated with a complex range of metabolic disturbances, including elevated triglycerides, high homocysteine levels, S-adenosylhomocysteine (SAH) buildup, imbalances in phospholipid metabolism, elevated triglycerides (hypertriglyceridemia) and low HDL cholesterol. These metabolic changes contribute to an increased risk of cardiovascular disease (CVD) and neurocognitive disorders in people living with HIV.

..

Postmenopausal women often experience elevated homocysteine (Hcy) due to declining estrogen, which impairs choline-to-phospholipid conversion and reduces the methyl group supply required to break down Hcy. High Hcy levels drive accumulation of S-adenosylhomocysteine (SAH), a potent inhibitor of methylation (DNA/phospholipid), reducing phosphatidylcholine synthesis and lowering acetylcholine.

Elevated Hcy in menopause is linked to cardiovascular disease, endothelial dysfunction, and osteoporosis.

..

Hcy/SAH/MetS)
Motor Neurone Disease (MND)
Spondylosis

Research into MND often considers metabolic dysfunction, including elevated homocysteine (Hcy) levels and S-Adenosyl-L-homocysteine (SAH), which may relate to increased metabolic syndrome (MetS) risks or cellular toxicity.

..

S-Adenosylhomocysteine (SAH) is the immediate precursor to homocysteine (Hcy) in the methionine cycle, formed when S-adenosylmethionine (SAM) donates a methyl group.

The confluence of hypomethylation, high S-adenosylhomocysteine (SAH), elevated homocysteine, histamine, unmetabolized folic acid (UMFA), and metabolic syndrome represents a complex disruption of the one-carbon metabolism cycle.

TMG restores SAMe levels.
SAMe increases Glutathione production.
Glutathione directly breaks down Acetaldehyde.
Zinc/Magnesium fuel the entire methylation cycle.

..

Metabolic Syndrome
Hormone Disfunction
Impaired Gene Expression
Menopause Low Estrogen
Low Testosterone
Spondyloarthropathies
Ankylosing Spondylitis
Psoriatic Arthritis
Diabetes
Autism
HIV
Lipodystrophy Syndrome
Lipid Triglycerides Abnormalities
Bad Cholesterol LDL
Histamine Degradation

Motor Neurone Disease (MND) ALS Lou Gehrig's disease & Spondylosis

Homocysteine (Hcy) and SAH Buildup

Hyperhomocysteinemia
Hypomethylation

Thyroid Disorders
Insulin Resistance

Estrogen Hormone Disorders

Acetylcholine and Phospholipid Enzyme Issues

..

N-acetylcysteine (NAC) helps S-adenosyl-L-methionine (SAMe) primarily by synergistically boosting antioxidant defenses and protecting liver function. NAC increases glutathione (GSH) levels—the body's main antioxidant—while SAMe drives methylation reactions; together, they enhance detoxification and protect against toxicity better than either compound alone.

Choline acts as a precursor to SAM-e by supplying methyl groups via its metabolite, betaine, to convert homocysteine back into methionine, which is then converted into S-adenosyl-L-methionine (SAMe).

N-Acetyl-L-cysteine (NAC) is most stable in water within a slightly acidic to neutral range, typically around pH 2–3 for maximum stability against oxidation, or pH 5-7 for general solubility. While it can be stable at higher pH, NAC is prone to oxidation in neutral/alkaline environments (pH > 7) to its dimer, diacetylcysteine.

..

S-adenosylhomocysteine (SAH), homocysteine (Hcy), and catechol-O-methyltransferase (COMT)

COMT Gene Variant
Val158Met Polymorphism
Catecholamine

https://www.mthfrsolve.com/blog/slow-comt-the-definitive-clinical-guide-for-testing-and-optimization